Ahmed ElkoumiOmar ElkoumiMohamed Hamouda ElkasabyHuzifa KhitiyMariam Khaled ElbairyAhmed TawfkOmar K. HabibAbeer Shaalan2025-01-142025-01-142025-01-09Elkoumi, A., Elkoumi, O., Elkasaby, M. H., Khitiy, H., Elbairy, M. K., Tawfik, A., Habib, O. K., & Shaalan, A. (2025). Survival benefit of cancer-directed surgery and the role of adjuvant therapy in malignant major salivary gland cancers: a propensity score matched retrospective analysis. Oral and Maxillofacial Surgery, 29(1). https://doi.org/10.1007/s10006-024-01316-0https://doi.org/10.1007/s10006-024-01316-0https://repository.msa.edu.eg/handle/123456789/6300Q1Background The primary objective of this study was to assess the beneft of cancer-directed surgery (CDS) on both overall survival (OS) and cancer-specifc survival (CSS) of patients with malignant major salivary gland cancers (MMSGCs). The secondary objective was to explore the benefts of adjuvant therapy on the survival outcomes of these patients. Methods Patients diagnosed with MMSGC were extracted from the SEER database and subsequently categorized into two cohorts: CDS and non-CDS. Propensity score matching (PSM) was used to mitigate confounding variables. The survival beneft associated with CDS was evaluated using Kaplan–Meier analysis, log-rank tests, and Cox proportional hazard models. Furthermore, the impact of adjuvant radiotherapy and chemotherapy was explored within the CDS subgroup. Results A total of 7,029 patients with MMSGC were included. PSM was performed and resulted in a matched cohort between both groups, including 595 patients in each group. Multivariable Cox proportional hazard indicated that patients who received CDS had better OS (HR: 0.45, 95% CI [0.39 to 0.52], P<0.001) and CSS (HR: 0.46, 95% CI [0.40 to 0.52], P<0.001). The 5- and 10-year OS for the CDS group was 42% (95% CI, 38 −46%), and 25% (95% CI, 21 −29%) consecutively, while the 5- and 10-year OS for the non-CDS group was 20% (95% CI, 17 −24%), and 12% (95% CI, 9.7 −16%) consecutively. Moreover, patients with younger age, localized tumors, and lower TNM stage could beneft more from CDS. Radiotherapy as adjuvant therapy was found to be benefcial (HR: 0.69, 95% CI [0.55–0.85], p<0.001), while chemotherapy could not signifcantly beneft these patients. Conclusion CDS improved the OS and CSS survival in MMSGC patients. Specifc patient subgroups seemed to have a superior beneft from CDS. Adjuvant radiotherapy could help enhance the survival outcomes of these patients while chemotherapy could not.en-USSalivary gland cancer · Cancer-directed surgery · Adjuvant therapy · Propensity score matchingArticlehttps://doi.org/10.1007/s10006-024-01316-0